PCa cases are stratified into low/intermediate-risk and high-risk groups according to the definition of the European Association of Urology (EAU) based on the serum prostate specific antigen (PSA) level, Gleason score and clinical stage of prostate cancer patients. This evidence concerns the gene KLK3 and Familial prostate cancer.